EnterNext welcomes Genfit on Euronext's market in Paris

Jean-François Mouney, CEO of GENFIT, opens the European trading day in Paris.

Genfit is a leading European biopharmaceutical group. It specializes in the discovery and development of drugs for preventing and treating risk factors related to cardiometabolic pathologies (atherosclerosis, dyslipidemias, hypertension, diabetes, obesity, etc.) and inflammatory diseases. Genfit's development model, which allies internally financed research programs with partner-supported programs, allows it to manage the associated risks while generating value for its shareholders. Working both on its own behalf and for large industrial pharmaceutical group accounts, Genfit has developed a rich and diversified portfolio of promising drugs in the clinical and pre-clinical development phases.